Crude Oil Rises Over 1%; Conagra Brands Earnings Top Views
U.S. stocks mixed: Dow fell over 200 points, while Nasdaq and S&P 500 rose; inflation cooled and Q2 GDP was revised higher.
Stocks · News reference
Rafael Holdings Announced Topline Efficacy And Safety Data From Its Cyclo Therapeutics Subsidiary’s Phase 3 TransportNPC Study Evaluating Trappsol Cyclo In 94 Patients Diagnosed With Niemann-Pick Disease Type C; Trappsol Cyclo Did Not Achieve Statistical Significance
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why Is Rafael Stock Falling Wednesday?
Rafael Holdings (NYSE: RFL) stock tumbles after its Phase 3 TransportNPC study of Trappsol Cyclo misses its primary endpoint.
Rafael Holdings shares are trading lower after its subsidiary reported that Trappsol Cyclo missed the primary endpoint in a pivotal Phase 3 study.
Nasdaq Gains Over 100 Points; Jabil Posts Upbeat Earnings
U.S. stocks rose, led by tech, as Jabil beat Q4 estimates and raised FY2027 guidance; oil and gold also climbed.